Expanded access to experimental treatment for recurrent glioblastoma
Part of Cancer clinical trials.
This trial offers expanded access to an experimental treatment (RZ-001) for people with recurrent glioblastoma (a type of brain cancer) that has grown again after initial treatment. It is for those who cannot join other clinical trials and aims to provide possible treatment options when standard ones have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (age 18 or older, or the legal age in your country).
- You must have a confirmed diagnosis of Grade 4 astrocytoma or glioblastoma (GBM) based on the 2021 WHO classification.
- Your tumor must have recurred (grown again) and show measurable contrast-enhancing disease on MRI (at least 1 cm in size).
- The recurrence must be localized (one or a few areas) – not spread throughout the brain or into the ventricles.
- You must not have had other cancers within the last 5 years.
- You must not have had certain treatments recently: chemotherapy within 4 weeks, or immunotherapy, antibody therapy, gene therapy, vaccine therapy, or others within 3 months; radiation within 12 weeks.
- Your tumor must not have spread outside the brain (no extracranial metastases).
- You cannot be currently eligible for another RZ-001 clinical trial, and you must not have received RZ-001 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called RZ-001 combined with an antiviral drug (valganciclovir) for people with glioblastoma, a serious brain tumor. The goal is to see if the combination is safe and can help shrink or slow the tumor.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests two new investigational drugs (ABBV-637, ABBV-155) combined with another drug (ERAS-801) for people with glioblastoma. The goal is to see if this combination can shrink the tumor or slow its growth. You need to have a specific genetic marker (EGFR amplification) in your tumor to be eligible.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests a new drug called ACT001 for people with recurrent glioblastoma (a type of brain cancer) whose tumors have a specific marker (STAT3-high). The drug targets that marker to try to stop the tumor from growing.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.